Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Hepatitis C × elbasvir-grazoprevir drug combination × Clear all

Phase

Phase 3 1 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Hepatitis C 1 Carcinoma, Hepatocellular 1

Interventions

ledipasvir, sofosbuvir drug combination 2 Ribavirin 2 pembrolizumab 1 grazoprevir 1 elbasvir-grazoprevir drug combination 1 elbasvir 1 Sorafenib 1 Sofosbuvir 1 Medical Marijuana 1 Immunoenzyme Techniques 1 Chromatography, High Pressure Liquid 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02940496 2025-07-15

Pembrolizumab (MK-3475) in Hepatocellular Carcinoma

M.D. Anderson Cancer Center

Phase 2 Completed

15 enrolled 8 charts

Gastrointestinal

Hepatitis C, Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon ⚡